Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC

IF 4.5 2区 医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-09-23 DOI:10.1016/j.lungcan.2024.107962
Michael Snider , Joseph K. Salama , Matthew Boyer
{"title":"Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC","authors":"Michael Snider ,&nbsp;Joseph K. Salama ,&nbsp;Matthew Boyer","doi":"10.1016/j.lungcan.2024.107962","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Surgery is the standard of care for early-stage non-small cell lung cancer (NSCLC), with SBRT reserved for patients who are not surgical candidates. We hypothesized overall survival (OS), lung cancer-specific survival (LCSS), progression free survival (PFS), and recurrence rates following SBRT or surgery in medically operable patients with Stage I NSCLC from the Veterans’ Health Care System (VAHS) would be equivalent.</div></div><div><h3>Materials and methods</h3><div>Medically operable patients diagnosed with Stage I NSCLC between 2000–2020 from the VAHS, determined by an FEV1 or DLCO &gt; 60 % of predicted and Charlson comorbidity index (CCI) of 0 or 1, treated with SBRT or surgery were identified. SBRT patients were propensity score matched in a 1:1:1 ratio to those undergoing resection (SBRT:lobectomy:sub-lobar resection). OS, LCSS, and PFS and site of recurrence were determined.</div></div><div><h3>Results</h3><div>103 patients were included in each cohort. With a median follow-up of 7.9 years 5-year OS for all patients was 51 % (95 % CI 46–57 %). After propensity score matching, OS (HR 2.08, 1.59), LCSS (HR 2.28, 1.97), and PFS (1.97, 1.45) were significantly worse with SBRT compared to either lobectomy or sub-lobar resection, respectively, (p &lt; 0.05 for each comparison). Regional recurrence was significantly higher following SBRT (15.5 % vs 6.8 % or 4.9 %; <em>p</em> &lt; 0.05), but there was no significant difference in local (28.2 % vs 21.4 % or 21.4 %; <em>p</em> &gt; 0.05) or distant recurrence (10.7 % vs 9.7 % or 13.6 %; <em>p</em> &gt; 0.05) when compared to lobectomy or sub-lobar resection, respectively.</div></div><div><h3>Conclusion</h3><div>In medically operable patients, OS, LCSS, and PFS following either lobectomy or sub-lobar resection were superior to that for SBRT for Stage I NSCLC, likely due in part to higher regional recurrence following SBRT. This suggests that pulmonary function test results and CCI alone are insufficient to define a cohort of medically operable patients suited for SBRT. These data support strategies to overcome regional recurrences seen with SBRT.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"197 ","pages":"Article 107962"},"PeriodicalIF":4.5000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224004963","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Surgery is the standard of care for early-stage non-small cell lung cancer (NSCLC), with SBRT reserved for patients who are not surgical candidates. We hypothesized overall survival (OS), lung cancer-specific survival (LCSS), progression free survival (PFS), and recurrence rates following SBRT or surgery in medically operable patients with Stage I NSCLC from the Veterans’ Health Care System (VAHS) would be equivalent.

Materials and methods

Medically operable patients diagnosed with Stage I NSCLC between 2000–2020 from the VAHS, determined by an FEV1 or DLCO > 60 % of predicted and Charlson comorbidity index (CCI) of 0 or 1, treated with SBRT or surgery were identified. SBRT patients were propensity score matched in a 1:1:1 ratio to those undergoing resection (SBRT:lobectomy:sub-lobar resection). OS, LCSS, and PFS and site of recurrence were determined.

Results

103 patients were included in each cohort. With a median follow-up of 7.9 years 5-year OS for all patients was 51 % (95 % CI 46–57 %). After propensity score matching, OS (HR 2.08, 1.59), LCSS (HR 2.28, 1.97), and PFS (1.97, 1.45) were significantly worse with SBRT compared to either lobectomy or sub-lobar resection, respectively, (p < 0.05 for each comparison). Regional recurrence was significantly higher following SBRT (15.5 % vs 6.8 % or 4.9 %; p < 0.05), but there was no significant difference in local (28.2 % vs 21.4 % or 21.4 %; p > 0.05) or distant recurrence (10.7 % vs 9.7 % or 13.6 %; p > 0.05) when compared to lobectomy or sub-lobar resection, respectively.

Conclusion

In medically operable patients, OS, LCSS, and PFS following either lobectomy or sub-lobar resection were superior to that for SBRT for Stage I NSCLC, likely due in part to higher regional recurrence following SBRT. This suggests that pulmonary function test results and CCI alone are insufficient to define a cohort of medically operable patients suited for SBRT. These data support strategies to overcome regional recurrences seen with SBRT.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
可接受药物手术的 I 期 NSCLC 患者接受 SBRT 或手术后的存活率和复发率。
目标:手术是治疗早期非小细胞肺癌(NSCLC)的标准方法:手术是早期非小细胞肺癌(NSCLC)的标准治疗方法,SBRT 则是为不适合手术的患者保留的治疗方法。我们假设,退伍军人医疗保健系统(VAHS)中可接受医疗手术的 I 期 NSCLC 患者接受 SBRT 或手术治疗后的总生存期(OS)、肺癌特异性生存期(LCSS)、无进展生存期(PFS)和复发率是相同的:对退伍军人医疗保健系统(VAHS)中 2000-2020 年间确诊为 I 期 NSCLC 的可进行医疗手术的患者进行鉴定,患者的 FEV1 或 DLCO > 预测值的 60% 且 Charlson 合并症指数 (CCI) 为 0 或 1,接受 SBRT 或手术治疗。SBRT患者与接受切除术的患者按1:1:1的比例进行倾向评分匹配(SBRT:肺叶切除术:肺叶下切除术)。确定了OS、LCSS、PFS和复发部位:每个队列共纳入103名患者。中位随访时间为7.9年,所有患者的5年OS为51%(95% CI 46-57%)。经过倾向评分匹配后,与肺叶切除术或肺叶下切除术相比,SBRT的OS(HR 2.08,1.59)、LCSS(HR 2.28,1.97)和PFS(1.97,1.45)分别显著低于肺叶切除术或肺叶下切除术(P 0.05)或远处复发(10.7% vs 9.7% 或 13.6%;P > 0.05):结论:对于可接受药物治疗的患者,肺叶切除术或肺叶下切除术后的OS、LCSS和PFS均优于SBRT治疗I期NSCLC,部分原因可能是SBRT治疗后区域复发率较高。这表明,仅凭肺功能测试结果和CCI还不足以确定哪些患者适合接受SBRT治疗。这些数据为克服 SBRT 区域复发的策略提供了支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
期刊最新文献
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1